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The aim of this study was to evaluate interruption of treatment with biological drugs and tofacitinib 
due to adverse events in patients with rheumatoid arthritis. A systematic review was performed in the 
electronic databases MEDLINE, Cochrane, Scopus, CRD, IPA, Lilacs and Scielo. Case reports addressing 
interruption of treatment due to any adverse event related to abatacept (ABA), adalimumab (ADA), 
anakinra (ANA), certolizumab pegol (CER), etanercept (ETA), golimumab (GOL), infliximab (IFX), 
rituximab (RTX), secukinumab (SEC), tocilizumab (TCZ), tofacitinib (TOF) or ustekinumab (UST) 
in rheumatoid arthritis patients were evaluated. Baseline data, patient profile, previous and current 
treatments, cause of discontinuation and information on reintroduction of treatment were extracted 
from the case reports. One hundred and fifty-four studies (154 patients) reported 162 discontinuations 
of rheumatoid arthritis treatment due to adverse events (ETA = 57; IFX = 46; ADA = 32; TCZ = 13; 
RTX = 5; ANA = 3; GOL = 2; ABA = 2; TOF = 1; CER = 1; SEC = 0 and UST = 0). The mean age of 
patients was 56 (± 12.1) years and 82% were female. Seventy-four adverse events were confirmed (related 
to used drug), and 138 were observed in patients using anti-TNF. The most common adverse events were 
infections (21%), skin disease (15%), autoimmune disease (13%) and hematological disorders (9%). 
Case reports are important in the detection of rare adverse events and should be considered in the choice 
of appropriate therapy for patients.
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INTRODUCTION 
Rheumatoid arthritis (RA) is a chronic and systemic 
autoimmune disease, and pathogenesis comprises 
environmental triggers (i.e. cigarette smoking) and 
multiple genetic factors (Mateen et al., 2016; Kim et al., 
2017). With an estimated global prevalence of 1%, RA 
affects primarily the small joints of the upper and lower 
extremities, and includes extra-articular manifestations, 
such as pulmonary disease and rheumatoid nodules 
(Kelmenson, Demoruelle, Deane, 2016; Smolen, Aletaha, 
McInnes, 2016; Lage-Hansen et al., 2017). RA causes 
substantial impairment in patients’ quality of life, as the 
decline in physical function hinders the ability to perform 
daily activities, including the capacity to work. As RA 
induces a significant burden for patients and society, 
control of the disease in order to reduce or avoid further 
damage is crucial (Singh et al., 2016; Smolen, Aletaha, 
McInnes, 2016).
At first, non-steroidal anti-inflammatory drugs were 
used to reduce symptoms such as pain and joint swelling 
in patients diagnosed with RA. At present, EULAR 
(European League Against Rheumatism) guidelines 
recommend that patients initiate treatment with a disease-
modifying anti-rheumatic drug (DMARD) from the time 
of the diagnosis. In the absence of achievement of the 
treatment goal (i.e. inflammation reversal), the switch 
to a different DMARD or the addition of a biological 
or synthetic DMARD are strategies recommended by 
the guidelines (Murota et al., 2016; Zhou et al., 2016; 
Choy et al., 2017). The Food and Drug Administration 
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(FDA, www.fda.gov) and European Medicines Agency 
(EMA, http://www.ema.europa.eu) currently approve 
biological DMARDs for RA treatment comprised of 
TNF inhibitors: adalimumab (ADA), etanercept (ETA), 
infliximab (IFX), certolizumab pegol (CER), golimumab 
(GOL); the anti-B-cell agent rituximab (RTX); the 
anti-T-cell co-stimulation agent abatacept (ABA); the 
interleukin-6 receptor inhibitor tocilizumab (TCZ); the 
interleukin-1 receptor antagonist anakinra (ANA); the 
interleukin 17A inhibitor secukinumab (SEC) and the 
interleukin 12 and 23 inhibitor ustekinumab (UST) (Scott 
et al., 2016; Smolen, Aletaha, McInnes, 2016; Tarp et 
al., 2017). Tofacitinib (TOF), despite being a synthetic 
DMARD, is currently incorporated in guidelines as 
a therapeutic choice after failure of other DMARDs 
(Smolen et al., 2017). This drug is a selective Janus 
kinase (JAK) inhibitor that preferentially inhibits JAKs 
1 and 3 (Dhillon, 2017).
The recent use of these agents markedly improved 
RA treatment responses, reducing pain and stiffness and 
enhancing patient mobility (Pal et al., 2016). Despite 
several randomized controlled trials and meta-analyses 
addressing the use of biologic agents and TOF for RA 
treatment being published in recent years, evidence 
regarding discontinuation rates due to adverse events 
(AE) with these drugs is still weak. In addition, accurate 
information concerning AE and tolerability outcomes 
in clinical practice is difficult to gather (Abasolo et al., 
2015). Hence, considering the severity and relevance 
of RA, and the need for evidence regarding tolerability 
and safety profiles of biological agents, the main goal 
of the present study was to systematically evaluate the 
reasons for treatment discontinuation and whether the 
relationship between the AE and the treatment in use 
was confirmed in patients with RA. This manuscript is 
part of a larger project that evaluates all types of studies 
concerning treatment interruption in RA patients. Case 
reports were selected as the primary source of information 
for this systematic review because they are useful in the 
recognition of singularities of therapies, and are usually 
the first studies that report new and rare AE, describing 
non-ordinary situations. Furthermore, they are suitable 
to generate hypotheses, and can be used to explore issues 
further (Hung et al., 2015).
MATERIAL AND METHODS
This study is part of a project that evaluates the 
reasons for discontinuation of biological treatments in 
RA in all types of studies (PROSPERO register number 
42016033706).
A systematic review was performed in accordance 
with the Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA) guidelines and Cochrane 
Collaboration recommendations. Electronic searches were 
conducted in the databases Medline (Pubmed), Lilacs, 
Scielo, Cochrane Library, Scopus, Center for Reviews 
and Dissemination and International Pharmaceutical 
Abstracts. The descriptors for treatment discontinuation/
interruption, biological agents (ABA, ADA, ANA, CER, 
ETA, GOL, IFX, RTX, TCZ, SEC and UST) and TOF, 
and rheumatoid arthritis were combined with Boolean 
operators (supplementary material). A manual search 
of the published articles was also performed. Studies in 
English, German, French, Italian, Spanish and Portuguese, 
published until December 2017, were included.
Study selection
Inclusion criteria
Case report studies reporting data on discontinuation 
due to AE of any of the biological drugs under evaluation 
or TOF at any dose/regimen in patients with RA at 
any stage were included, including those with any 
comorbidity.
Exclusion criteria
We excluded studies that did not mention interruption 
to treatment, or where the patient died without interrupting 
the treatment.
Data screening
Two independent reviewers screened titles and 
abstracts to identify irrelevant records. In a second stage, 
full-text articles were independently evaluated by these 
two researchers to select studies for inclusion; differences 
were resolved by consensus with a third reviewer.
Data extraction
Two reviewers independently extracted into 
Excel spreadsheets data from the selected studies on: (i) 
patient characteristics (age, gender, time of disease), (ii) 
clinical data (comorbidities, previous medication), (iii) 
therapies (biological drug or TOF dosage, administration 
route, concomitant drugs), (iv) AE (time of biological 
drug or TOF use until AE, first symptoms, reason for 
discontinuation, if the AE stopped after discontinuation 
and information about treatment re-introduction) and (v) 
information about the potential relationship of the AE 
with the drug.
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Analyses
All discontinuations due to AE related to the 
biological drug or TOF in RA patients were described. 
These AE were considered as adverse drugs reactions. 
When a confirmed relationship was reported between the 
reaction onset and the drug, they were described separately 
one by one in descriptive tables; whereas for AE possibly 
or probably related to the drug (no confirmed relationship 
between the AE and the biological agent), events were 
described according to the system affected (i.e. skin 
diseases, hematological disorders). Qualitative and 
quantitative comparisons were performed when possible to 
obtain a broader overview of all reported discontinuations.
RESULTS
This study is part of a project that aims to explore 
the discontinuation of biological treatment for RA reported 
in all types of studies. In the search for articles, all study 
types were searched simultaneously. In the current article, 
only the case reports are described.
In the first stage of the search for articles, 4,418 
articles were found (Figure 1). Of these, 643 were 
duplicates and 2,766 were excluded based on their title 
and/or abstract. The other remaining 1,009 articles were 
fully read. Among these articles, 162 were the case reports 
included in this study. When interruptions due to an AE 
were reported for more than one drug in the same case 
report, multiple registers concerning each drug were 
created in order to separately describe each one of the AE, 
being called A, B and so on.
A total of 154 articles were found (supplementary 
material), describing 162 case reports that met the 
inclusion criteria. In descending order, the numbers of case 
reports found for each drug were: ETA = 57; IFX = 46; 
ADA = 32; TCZ = 13; RTX = 5; ANA = 3; GOL = 2; ABA 
= 2; TOF=1 and CER=1. No reports about interruption of 
ustekinumab or secukinumab in RA patients were found.
Of the 162 cases, 128 (82%) occurred in female 
patients. The mean age of all patients was 56 (± 12.1) 
years, and the patients’ ages ranged from 24 to 80 years 
old. The disease duration ranged from 8 months to 48 
years. Thirty-eight (23%) case reports described the use 
of at least one previously known biological agent, and 
76 (47%) described the concomitant use of synthetic 
DMARD (Table I).
The time of treatment until the onset of the AE that 
led to drug interruption ranged from two days to seven 
years. There were 66 (41%) confirmed AE (Table II), that 
is cases where the AE was certainly related to the use of the 
evaluated drug: 22 cases related to IFX therapy; 19 to ETA; 
FIGURE 1 - Flowchart of study selection.
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16 to ADA; 6 to TCZ; 1 to ANA; 1 to GOL and 1 to RTX. 
The other AE were suspected or probably associated with 
the drug, but without confirmation. Regarding the reported 
comorbidities, the most frequent was hypertension (12% 
- 19 patients), followed by chronic C hepatitis, thyroiditis 
and Sjörgen syndrome (3% - 5 patients each).
One hundred and thirty-eight (85%) events happened 
in patients using anti-TNF therapy (ADA, CER, ETA, 
GOL or IFX). Of these patients, 12 (9%) restarted the 
same drug after resolution of the AE, and another 29 (21%) 
switched to another drug of the same class (anti-TNF). 
Of those who returned to the same drug, in nine (75%) 
patients the AE occurred again and the medication had to 
be stopped once more. Of those who switched to another 
anti-TNF, 11 (38%) experienced an AE that led to further 
discontinuation of treatment.
Of the 13 patients who discontinued treatment while 
using anti-TNF and started a drug from another class, 
only one study (8%) described a further discontinuation 
of treatment. However, it is important to mention that 
some serious AE may have occurred after the articles were 
published and, therefore, may not have been documented.
Considering the 162 AE, 33 (21%) were related to 
serious infections, 25 (15%) to skin diseases, 21 (13%) 
to autoimmune reactions, 14 (9%) to hematological 
disorders, 11 (7%) to allergies and 8 (5%) to hepatitis, 
while neoplasias, infusion reactions and reactions in 
the cardiovascular system represented 6 (4%) AE each 
(Figure 2).
Of the 95 remaining AE that were considered suspect 
or possible, 20 (21%) were related to serious infections, 
14 (15%) to skin diseases and 11 (12%) to autoimmune 
diseases, whereas allergies, hepatitis and hematological 
disorders occurred in six (6%) patients each.
Eight AE that led to treatment discontinuation 
occurred in patients who had already had a biological 
drug suspension due to an AE. These cases are described 
below. One patient presented three interruptions due to 
allergic reactions (using ADA, ETA and ANA) (Desai et 
al., 2009). Another patient presented labial angioedema 
and tongue swelling during treatment with ADA. She 
started to use ETA, and after three months experienced 
epistaxis and bleeding in the mouth, leading to treatment 
discontinuation. She returned to ADA, and after six 
months presented erythema at the injection sites. The 
treatment was stopped and she started RIT, without report 
of any more AE (Abadoglu et al., 2011). One woman 
experienced hypertension and headaches that resulted in 
treatment discontinuation. She started treatment with IFX, 
and after the third dose a complete heart block occurred. 
The patient stopped IFX (Sote, Green, Maddison, 2008). 
In other case report, a woman experienced an infusion 
reaction after 40 weeks of IFX. She stopped IFX and 
started ETA. After 19 months, she developed cellulitis 
in the arm and discontinued ETA (Deniz et al., 2012). A 
woman developed severe angioedema after the second 
IFX administration and stopped treatment. She started 
ADA, and after two months presented a psoriatic-like 
skin reaction. She discontinued ADA and started RIT with 
methotrexate (Mourao et al., 2010). A patient presented 
an infusion reaction after IFX administration. Treatment 
was interrupted and restarted after four weeks using 
concomitant premedication. This patient interrupted the 
treatment again due to scleredema (Ranganathan, 2005).
FIGURE 2 - Most common adverse events according to the type of rheumatoid arthritis treatment.
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DISCUSSION
This is a descriptive study describing only AE 
with biologicals and TOF that led to discontinuation of 
treatment in patients with rheumatoid arthritis. Only 
case reports were selected for this systematic review. 
Case control studies are important because they usually 
describe rare situations found in clinical practice, at any 
moment, and not just tied to the conduction period of a 
study. Thus, they are of paramount importance to detect 
rare AE. Furthermore, case reports can describe a situation 
experienced by a patient with a specific condition (that 
might not be eligible for other types of studies), and allows 
exploration of this data, presenting relevant information 
for exceptional circumstances. 
An important factor to observe when analyzing 
the number of reports on AE is the time that each drug is 
on the market. While ABA, ADA, ANA, ETA, IFX and 
RTX have been marketed for more than 10 years, CER, 
GOL and TCZ are more recent and have been approved 
by the FDA for eight, seven and six years, respectively. 
Therefore, some medications have been used for less time 
and in less quantity; logically, there are fewer studies and 
reports in the literature on their use.
In the included case reports, we did not find data 
on previous treatments for all patients before starting 
the biological drug. However, according to international 
recommendations (EULAR, ACR - American College 
of Rheumatology, and NICE - The National Institute 
for Health and Care Excellence), patients should start 
TABLE I - Characteristics of included case reports
 
Drug N Female Mean age (range)
Disease 
duration
Previous 
biological 
drug
Association 
with dmard
Time until 
the AE 
appeared
Confirmed 
AE
Re-introduction 
of biologic drug*
Ae after drug 
reintroduction
ABA 2 1 55.7 (55-63) 13 months - 7 years 0 2 5-15 months 0 0 NA
ADA 32 27 53.8 (32-78) 8 months – 30 years 9 16
2 weeks - 6 
years 16
3 ADA 
4 ETA 
5 RIT 
2 IFX 
1 ABA 
1 ANA+IFX
2 
3 
1 
1 
ANA 3 3 58 (47-75) 11-16 years 2 1 2-21 months 1 1 ANA 1 ADA
 
1
CER 1 1 71 8 years 0 1 4months 0 0 NA
ETA 57 44 53.3 (24-80) 1-48 years 13 16 1 dose – 6 years 19
4 ADA 
8 ETA 
2 RIT 
2 ABA 
2 TCA 
1 CER
2 
6 
 
 
 
1
GOL 2 2 52.5 (47-58) 9 years 1 1 9months – 3 years 1 0 NA
IFX 46 36 56.8 (33-80) 14months - 33 years 2 33
2 days – 7 
years 22
16 ETA 
2 ADA 
1 IFX 
1 RIT
4 
 
1
RTX 5 5 51.2 (42-60) 10-18 years 3 1 6 days – 14 months 1 2 RIT 1
TCZ 13 11 59.1 (37-79) 3-24 years 8 4 4 weeks-26 months 5
2 CER 
1 RIT 
2 TCZ
 
 
1
TOF 1 1 72 12 years NR NR 5 months 0 0 NA
N=number of patients; AE=adverse event; ABA=abatacept; ADA=adalimumab; ANA=anakinra; CER=certolizumab; ETA=etanercept; 
GOL=golimumab; IFX=infliximab; RTX=rituximab; TCZ=tocilizumab; NA=not applicable; NR=not related. * related in the article
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TABLE II - Description of confirmed adverse event
Drug Age Previously biological drug Time of treatment Adverse event
AE disappeared 
with suspension of 
biological drug
ADA
32 2 weeks labial angioedema and tongue swelling Y
32 ADA and ETA 6 months erythema at the injection sites lasting more than 24 hours Y
66 1 year Alopecia universalis Y
63 12 weeks Severe cutaneous reaction Y
51 4 months pustular drug eruption Y
55 10 weeks Neutropenia Y
55 9 months Tuberculosis Y
75 4 months Inrection with nocardia Y
51 6 months Generalized pustulosis N
33 INF 2 months psoriatic like skin reaction Y
60 INF 13 weeks Urticaria and angiedema-like skin reactions Y
35 ETA 2 months Autoimmune hepatitis Y
57 7 weeks Injection site reaction Y
64 7 months interstitial pneumonia Y
71 
52 INF and ETA
6 years 
4 months
Tuberculosis of the tongue 
lichenoid drug eruption
Y 
Y
ANA 52 21 months Interstitial granulomatous drug reaction Y
ETA
32 ADA 3 months epistaxis and bleeding in the mouth Y
50 INF 2 years extensive pulmonary nodulosis Y
44 ADA 2 weeks injection site reactions Y
70 8 months Lichen striatus Y
58 2 weeks leukocytoclastic vasculitis Y
61 2 months perforating folliculitis Y
66 2 years Demyelinating disorder Y
56 1 months Diffuse Alveolar Hemorrhage and Acute Respiratory Distress Syndrome *
70 8 weeks Dermatitis Y
52 40 weeks cold agglutinin disease Y
66 2 years Oligoarticular Septic Arthritis Y
64 ADA 1 weeks Lymphopenia Y
55 3 months Delayed multiple injection site reaction Y
33 ADA 6 months Tuberculose Y
30 2 months Psoriasis Y
80 INF 1 months subacute prurigo with eosinophilia Y
37 20 weeks etanercept-induced liver dysfunction Y
64 ADA 3 weeks Lymphopenia Y
33 ADA 1 months Allergic reaction Y
GOL 47 ADA 9 months Subacute Systemic Lupus Erythematous Y
IFX
49 4 doses Leprosy Y
78 ADA and ETA 6 weeks complete heart block Y
62 7 years Lymphoma Y
53 9 doses Leishmaniose visceral Y
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treatment with conventional DMARD before using a 
biological drug (Singh et al., 2012; NICE, 2013; Smolen 
et al., 2014). Most guidelines recommend biological 
exchange in case of discontinuation of a biological drug 
or TOF due to AE, but it is still not defined whether this 
exchange should be between the same class or not. In the 
case reports included in our study, we could not evaluate 
the recurrence of the AE when using drugs of the same 
class, as many of the reports were published soon after the 
resolution of the AE, without presenting the continuity of 
the treatment. An observational study that evaluated the 
exchange between anti-TNF (only ADA, ETA and IFX) in 
72 patients described that switching from one anti-TNF to 
another could be beneficial for patients treated first with a 
molecule with satisfactory efficacy, especially if that first-
line biological agent was a monoclonal antibody (ADA 
or IFX). On the other hand, if the patient was in primary 
failure and received ETA as first-line therapy, it would 
seem better to propose another class of biological therapy 
(Lequerre et al., 2015). 
The most commonly reported AE leading to 
treatment discontinuation presented on the case reports 
was serious infections. In a meta-analysis (Gartlehner et 
al., 2006) that evaluated the efficacy and safety of agents 
Drug Age Previously biological drug Time of treatment Adverse event
AE disappeared 
with suspension of 
biological drug
IFX
41 3 years hepatite autoimune Y
54 42 months Tuberculose Y
52 40 weeks Infusion reaction Y
74 INF and ETA 11 months Neuromeningeal Tuberculosis Y
76 4 months
Acute development of multiple 
keratoacanthomas and squamous cell 
carcinomas
NR
53 1 year visceral leishmaniasis infection Y
61 5 months perforating folliculitis Y
66 17 doses leishmaniose mucocutânea Y
59 18 months drug-induced lúpus Y
57 2 days cryptococcal infection N
33 4 months severe angioedema Y
60 6 doses hypersensitivity reaction Y
52 2 weeks infusion reaction Y
52 14 weeks Scleredema Y
37 8 weeks Serious hypersensitivity reaction Y
51 13 doses lupus erythematosus tumidus Y
80 3 months subacute prurigo with eosinophilia Y
38 7 doses Toxic hepatites Y
RTX 42 4 doses Knee tuberculosis and Immune 
Reconstitution Inflammatory Syndrome
N
TCZ
61 18 months focal endocapillary and mesangial proliferative glomerulonephritis Y
56 7 months chronic lymphoplasmocytic syaloadenitis Y
61 2 months allergic drug eruptions Y
56 6 months Weight Gain With Abdominal Enlargement Y
79 
55
6 doses 
4 weeks
Psoriasiform Rash 
photoallergic drug eruption
Y 
Y
ABA=abatacept; ADA=adalimumab; ANA=anakinra; CER=certolizumab; ETA=etanercept; GOL=golimumab; IFX=infliximab; RTX=rituximab; 
TCZ=tocilizumab; NR=not related; * Patient died 2 weeks after interruption.
TABLE II - Description of confirmed adverse event (cont.)
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(ABA, ADA, ANA, ETA, IFX and RTX) in RA patients 
who had previously failed with DMARD treatment, the 
incidence of serious infections was markedly higher in 
the biological agents group when compared to the placebo 
group. In that study, tuberculosis was the most common 
infection reported. Their systematic review included only 
articles published in English, and observational studies 
were elected to evaluate AE. Infusion reactions were the 
most reported AE for IFX, RTX and ABA, while injection 
site reactions, such as pruritus, rash, pain and erythema, 
were the most common for ETA, ADA and ANA. In our 
systematic review, infusion reactions were found in case 
reports of ADA (2), ETA (1) and IFX (3). 
A Cochrane systematic review was published 
in 2011 evaluating the cases of serious infections, 
tuberculosis reactivation, lymphoma and congestive heart 
failure caused by biological agents reported in controlled 
trials and extension studies. The authors concluded that 
the number of AE and discontinuation due to AE is higher 
in the immunobiologicals compared to placebo, but does 
not differ among the drugs (Singh et al., 2011). The first 
meta-analysis evaluating the rate of discontinuation of 
biological agents for rheumatoid arthritis (Souto, Maneiro, 
Gomez-Reino, 2016) used world drug registries and 
healthcare databases. Regarding TNF inhibitors, their 
comprehensive systematic review showed a higher rate 
of discontinuation due to AE for ADA and IFX when 
compared to ETA for all the evaluated periods (six months 
and one, two, three and four years). TCZ also presented 
more cases of discontinuation due to AE than ETA, and 
similar rates when compared to ADA and IFX. In our 
study, most of the case reports on drug interruption were 
related to ETA, followed by IFX and ADA. Due to the 
nature of the primary source of information used in our 
present systematic review, which may carry a publication 
bias, it is not possible to infer that ETA is more associated 
to AE leading to drug interruption. However, it is possible 
to notice that drug discontinuation with ETA was more 
reported in case reports when compared to the other 
addressed biological agents, a fact that should be better 
investigated.
 In the first mixed treatment comparison (MTC) 
meta-analysis addressing outcome tolerability in terms 
of discontinuation due to AE of ABA versus TNF 
inhibitors (Hochberg et al., 2013), the authors identified 15 
randomized, placebo-controlled trials through systematic 
review. Regarding tolerability outcomes for both periods 
evaluated (6 and 12 months), a higher probability of drug 
discontinuation due to AE was found for TNF inhibitors 
compared to ABA, indicating that the latter may have a 
better tolerability profile. The findings from our study 
corroborate the results obtained by this MTC (Hochberg 
et al., 2013), as the majority of case reports on drug 
interruption due to AE were related to the TNF inhibitors 
ETA (57), IFX (46) and ADA (31), while only two cases 
addressing ABA were retrieved. 
Among skin diseases, psoriasis, dermatitis and 
other serious skin reactions have been reported. Clinically 
important dermatological conditions in RA patients treated 
with anti-TNF were investigated by Flendrie et al. (2005). 
The cohort study evaluated 911 patients using ADA, ETA 
or IFX. Skin infections, eczema and drug-related eruptions 
were the most common events (33, 20 and 15 patients, 
respectively), whereas psoriasis was found in three 
patients. In our study, 25 skin disorders were reported, 
including psoriasis (seven case reports). TNF-alfa induced 
psoriasis was described previously in a systematic review, 
where the cessation of anti-TNF therapy may have resulted 
in resolution of half of the cases (Brown et al., 2017).
 Autoimmune reactions constituted the third most 
reported AE leading to biological discontinuation in case 
reports. Considering that the targets of the biological agents 
(cytokines and dysregulated cells of the immune system) 
are also crucial constituents of immune homeostasis, it is 
not astonishing that the use of these agents promoted AE 
in this system (Her, Kavanaugh, 2016). The association 
between biological agents and the development of new 
autoimmune diseases has already been described in the 
literature. Among the biological agents, the class of TNF 
inhibitors has been pointed out as the foremost related to 
development of systemic autoimmune reactions. Previous 
studies have indicated lupus as the most frequently 
induced disease, followed by vasculitis and sarcoidosis 
(Perez-Alvarez et al., 2013; Her, Kavanaugh, 2016). The 
development of lupus was described in two case reports 
as confirmed AE leading to drug discontinuation in our 
systematic review. Both reports were related to TNF 
inhibitors (GOL and IFX). Vasculitis was reported in one 
case with ETA and no report of sarcoidosis was retrieved. 
TNF inhibitors were also found to be associated with 
the appearance of psoriatic skin lesions, which has been 
reported by several observational studies in the last years 
(Ciccarelli et al., 2016). In our study, development of 
psoriatic skin lesions was described in three case reports 
as confirmed AE leading to biological discontinuation. 
Two of the three reports were on TNF inhibitors (ADA 
and ETA) and one was on TCZ. Finally, one case of 
autoimmune hepatitis was described with ADA. The 
development of drug-induced autoimmune hepatitis was 
reported in a few cases in the literature with the use of TNF 
inhibitors. Nevertheless, the appearance of the disease 
during the treatment course with a biological agent should 
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be carefully evaluated, since it may not necessarily reflect 
a de novo disease onset (Efe, 2013). Despite the severity 
of some autoimmune-induced diseases, the suspension 
of the biological agent usually improves the symptoms 
(Rubbert-Roth, 2012), as observed in all autoimmune-
induced reactions reported in the retrieved cases. 
The major limitation of the present study is the 
paucity of evidence obtained from case reports, which 
may carry a publication bias. Moreover, many case reports 
do not present patient histories, previous treatments or 
dose of the drug. In addition, many are written shortly 
after treatment discontinuation, not describing whether 
treatment was re-introduced. Nevertheless, in order to 
minimize the risk of bias, the comprehensive search 
performed in this study attempted to retrieve all published 
case reports on drug interruption with biologicals for RA 
treatment, in order to drawn a broader overview of the 
causes of drug discontinuation.
Despite the study limitations addressed above, our 
findings are in agreement with the results from other 
studies evaluating the safety and tolerability of biological 
agents for RA treatment.
The objective of the present study was not to 
generate new evidence, as it was not possible to perform 
any quantitative synthesis of the results. Our goal was to 
search for and describe rare AE and uncommon situations 
that may appear in patients using biological drugs or TOF 
for RA treatment during the last several years, and gather 
all this information in a single source of information.
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